Related Experiment Video

Updated: Aug 30, 2026

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation
08:35

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation

Published on: December 29, 2014

Initial predictors of development of pure red cell aplasia in myasthenia gravis after thymectomy

Shigeaki Suzuki1, Shigeru Nogawa, Kortaro Tanaka

  • 1Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Clinical Neurology and Neurosurgery
|December 4, 2003
PubMed

Insights

Pure red cell aplasia (PRCA) can occur in myasthenia gravis (MG) patients post-thymectomy. Japanese MG patients with thymoma, bulbar symptoms, and high anti-acetylcholine receptor antibodies face higher PRCA risks.

Area of Science:

  • Neurology
  • Hematology
  • Immunology

Background:

  • Pure red cell aplasia (PRCA) is a known complication of myasthenia gravis (MG).
  • Predicting PRCA development in MG patients remains challenging.
  • The association between MG, thymectomy, and PRCA requires further investigation.

Purpose of the Study:

  • To identify risk factors for PRCA development in myasthenia gravis patients.
  • To investigate the characteristics of MG patients who develop PRCA after thymectomy.

Main Methods:

  • Retrospective analysis of 135 myasthenia gravis patients.
  • Comparison of clinical characteristics between MG patients with and without PRCA.
  • Evaluation of thymoma, bulbar involvement, and anti-acetylcholine receptor (AChR) antibody levels.

Main Results:

  • Four out of 135 MG patients (2.9%) developed PRCA.
  • PRCA onset occurred post-thymectomy during MG remission.
  • Patients who developed PRCA had higher frequencies of thymoma, bulbar involvement, and high anti-AChR antibody levels.

Conclusions:

  • Japanese MG patients presenting with thymoma, bulbar involvement, and high anti-AChR antibody levels are at significant risk for developing PRCA after thymectomy.
  • Early identification of these risk factors may aid in monitoring and managing PRCA in MG patients.

More Related Videos

Isolation and Transplantation of Different Aged Murine Thymic Grafts.05:47

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...